SABCS 2025

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

Willow Lane Acquisition enters public markets with $10 per unit IPO, betting on selective dealmaking

Galaxy Surfactants (NSE: GALAXYSURF) Q3 FY26 results signal portfolio resilience as specialty growth offsets global surfactant pressures

Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms

Why Eli Lilly and Company is stockpiling a weight loss pill before the FDA has even said yes

Kazia Therapeutics (NASDAQ: KZIA) unveils immune-boosting effects of paxalisib in advanced breast cancer at SABCS 2025

Find out how Kazia Therapeutics’ paxalisib is breaking new ground in breast cancer immunotherapy. Read the latest clinical insights from SABCS 2025.

bySrinath

December 10, 2025

ATNM-400 from Actinium Pharmaceuticals (ATNM) shows breakthrough promise in resistant breast cancer

Actinium’s ATNM-400 shows potent activity in resistant breast cancer and TNBC. Find out what the new SABCS 2025 data reveal about this radiopharma candidate.

byVenkatesh

December 1, 2025

The Latest

Willow Lane Acquisition enters public markets with $10 per unit IPO, betting on selective dealmaking

Galaxy Surfactants (NSE: GALAXYSURF) Q3 FY26 results signal portfolio resilience as specialty growth offsets global surfactant pressures

Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms

Why Eli Lilly and Company is stockpiling a weight loss pill before the FDA has even said yes

Kazia Therapeutics (NASDAQ: KZIA) unveils immune-boosting effects of paxalisib in advanced breast cancer at SABCS 2025

ATNM-400 from Actinium Pharmaceuticals (ATNM) shows breakthrough promise in resistant breast cancer

Willow Lane Acquisition enters public markets with $10 per unit IPO, betting on selective dealmaking

Galaxy Surfactants (NSE: GALAXYSURF) Q3 FY26 results signal portfolio resilience as specialty growth offsets global surfactant pressures

Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms

Why Eli Lilly and Company is stockpiling a weight loss pill before the FDA has even said yes

Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue

Sumitomo Forestry expands U.S. housing footprint with $4.5bn Tri Pointe Homes acquisition

Applied Optoelectronics Inc. Texas expansion marks next phase in optical components reshoring push

What Patrick Dumont’s rise to CEO reveals about Las Vegas Sands Corp.’s post-founder strategy